The purpose of this study is to determine if sorafenib, capecitabine and oxaliplatin (SECOX) regimen is more effective than sorafenib alone in the treatment of advanced liver cancer.

Inclusion Criteria:

• Advanced or metastatic hepatocellular carcinoma (HCC) not suitable for surgery or various loco-regional therapies.
• Diagnosis of HCC confirmed either by cyto-histological confirmation or by non-invasive criteria according to the European Association for Study of Liver disease (EASL) criteria.
• Child-Pugh A or B7 cirrhosis.
• Eastern Co-Operative Group (ECOG) performance status ≤ 2.
• Life expectancy of ≥ 12 weeks.
• Adequate organ function (blood transfusion or use of biologic response modifiers is not permitted).
• Measurable disease with at least one lesion, which is at least 1 cm in one dimension on computed tomography (CT) or magnetic resonance imaging (MRI).
• Able and willing to meet all protocol-required treatments, investigations and visits.
• Signed written informed consent form.

Exclusion Criteria:

• Prior systemic therapy for advanced HCC.
• Central nervous system (CNS) metastasis.
• History of liver transplantation.
• Peripheral sensory neuropathy with functional impairment before the first cycle of treatment.
• History of cardiac disease.
• Uncontrolled hypertension.
• Women who are pregnant or breast-feeding, or women of child-bearing potential who are unable or unwilling to practice a highly effective means of contraception.
• Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of study results.